Track record · closed signal

AbbVie Inc (ABBV) — closed signal from April 29, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 28, 2026 — +31% at the close.

Predicted vs. what happened

ABBV price · publication thesis → realized outcomesplit-adjusted

$195.21 – $202.11Entry zone — fair-value band

$200.91Published — price the day we called it

$225.42Target — the price the thesis aimed for

$266.92Peak — highest point inside the window, not a realized return

$263.20Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 37 days.

At window close

+31%

realized, from the publication price to the last close inside the window

Peak gain

+32.9%

peak, from the publication price — not a realized return

S&P 500, same window

+4.4%

SPY over the identical days, dividend-adjusted

Window close

$263.20

last close inside the window, ended July 28, 2026

Peak price

$266.92

peak on July 28, 2026 — not a realized return

Days to target

The thesis — published April 29, 2026

Predicted growth

+13%

over the measurement window

Target price

$225.42

the price the thesis aimed for

Entry zone

$195.21 – $202.11

the fair-value band we waited for

Price at publication

$200.91

published April 29, 2026

Confidence

68%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

AbbVie looks positioned to bounce after a strong quarterly report and higher annual guidance. Sales strength from Skyrizi and Rinvoq helps offset pressure from Humira, and health-care demand tends to hold up in weak markets. However, high debt, weaker recent profit metrics, and ongoing Humira uncertainties limit conviction, and price swings may remain sizable.

Primary drivers

Quarterly beat and raised guidance shift the short-term story
Skyrizi and Rinvoq growth offsets Humira-related weakness
Healthcare demand gives the company defensive support
Price was oversold, improving the odds of a rebound

How it played out

ABBV: target reached in 37 days

Lyra published a short-term rebound thesis at 200.91, with 13% expected growth and a 225.42 target. The thesis pointed to a quarterly beat and raised guidance, growth from Skyrizi and Rinvoq offsetting Humira weakness, defensive healthcare demand, and an oversold price. It also flagged debt, weaker profit metrics, Humira uncertainty, and sizable price swings.

The price reached the target in 37 days. It later peaked at 266.92 on July 28, a 32.9% gain, and ended the window at 263.20. The thesis played out and the price exceeded the published target.

What happened during the window

On June 26, 2026, AbbVie announced U.S. approval of Skyrizi for pediatric use in psoriatic disease. On July 6, 2026, AbbVie announced European approval of Tepkinly with lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABBV signals